Teva Announces AZILECT® (Rasagiline Tablets) Data to Be Presented at the 16th Annual International Congress of …

JERUSALEM, Israel--(BUSINESS WIRE)--

Teva Pharmaceutical Industries Ltd. (TEVA) today announced that data from studies of AZILECT (rasagiline tablets) and Parkinsons disease (PD) will be featured at the 16th Annual International Congress of Parkinsons Disease and Movement Disorders in Dublin, Ireland, 17-21 June 2012.

More than fifteen abstracts will highlight data from ongoing and completed studies of PD and AZILECT, a MAO-B inhibitor for the treatment of PD, in the areas of pre-clinical, clinical and health economics research.

We are proud of the variety of topics and quality of research results that will be presented at MDS this year, said Dr. Michael Hayden, President of Global R&D and Chief Scientific Officer, Teva Pharmaceutical Industries Ltd. We are committed to ongoing collaboration with academia, medical institutions and patient advocacy groups to continue our understanding of the role AZILECT may play in the treatment landscape for the PD community patients, their families and friends, and healthcare professionals.

Presentations include:

Ongoing studies assessing effects of AZILECT treatment on motor and non-motor PD symptoms, both as monotherapy and when added to ongoing dopamine agonist therapy:

New clinical trial results:

ABOUT AZILECT

AZILECT tablets (rasagiline tablets) are indicated for the treatment of the signs and symptoms of Parkinson's disease both as initial therapy alone and to be added to levodopa later in the disease in patients with end-of-dose fluctuations

Patients should not take AZILECT if they are taking meperidine, tramadol, methadone, propoxyphene, dextromethorphan, St. Johns wort, cyclobenzaprine, or other monoamine oxidase inhibitors (MAOIs), as it could result in a serious reaction. Patients should inform their physician if they are taking, or planning to take, any prescription or over-the-counter drugs, especially antidepressants and ciprofloxacin. Patients with moderate to severe liver disease should not take AZILECT. Patients should not exceed a dose of 1 mg per day of AZILECT in order to prevent a possibly dangerous increase in blood pressure.

Original post:
Teva Announces AZILECT® (Rasagiline Tablets) Data to Be Presented at the 16th Annual International Congress of ...